Download Stanford Profiles: /viewCV - CAP Network

SANDHYA SRINIVAS, M.D.
Associate Professor of Medicine (Oncology)
Stanford University Medical Center
875 Blake Wilbur Drive
Stanford, CA 94305-5826
Work: (650) 725-2078
Personal History
Birthplace
Date of Birth
Citizenship
Education
1980-1986
1987-1989
1989-1991
1992-1995
Positions Held
1986-1987
1996-1997
1997-1999
6/01/99-8/31/99
9/01/99-8/31/02
9/01/02-8/31/03
9/01/03-8/31/06
9/01/06-8/31/11
Vellore, India
March 19, 1962
U.S.
M.B.B.S. - Madras Medical College, India
Clinical Sub-intern
Strong Memorial Hospital Cancer Center, Rochester, NY
Internship and Residency, Internal Medicine,
St. Mary’s Hospital, Rochester, NY
Postdoctoral Fellowship, Oncology
University of California, San Francisco, San Francisco, CA
Research Assistant Department of Microbiology
University of Rochester Medical Center, Rochester, NY
Assistant Clinical Professor of Medicine
VA Medical Center, Houston
Baylor College of Medicine, Houston, TX
Clinical Instructor
Veterans Affairs Palo Alto Health Care System
Stanford University Medical Center, Stanford, CA
Acting Assistant Professor of Medicine (Oncology)
Veterans Affairs Palo Alto Health Care System
Stanford University Medical Center, Stanford, CA
Assistant Professor of Medicine (Oncology)
Veterans Affairs Palo Alto Health Care System
Stanford University Medical Center, Stanford, CA
Assistant Professor of Medicine (Oncology) (extension)
Veterans Affairs Palo Alto Health Care System
Stanford University Medical Center, Stanford, CA
Assistant Professor of Medicine (Oncology)
Stanford University Medical Center, Stanford, CA
Associate Professor of Medicine (Oncology)
Stanford University Medical Center, Stanford, CA
1
Professional Certification
1987
ECFMG
1988
FLEX
1991
Medical License: California A049392
1992
Board Certified: Internal Medicine
1995
Board Certified: Hematology
1997
Board Certified: Oncology
2001
Recertification: Internal Medicine
2009
Recertified: Medical Oncology
Academic Memberships
1996American Society of Clinical Oncology
2002Association of Northern California Oncologists
Committees
1996
Residency Selection Committee, Baylor College of Medicine, Houston, TX
1997-2003
Blood Transfusion Committee
1997-2003
Veterans Affairs Palo Alto Health Care Services
Cancer Care Committee
2002National Comprehensive Cancer Network Prostate Committee
2002Data Safety Monitoring Committee, Stanford Cancer Center
2002Intern Selection Committee, Department of Medicine, Stanford University
2005-2008
CME Sub Committee, American Society of Clinical Oncology
2007Co-director, Med X, Oncology Inpatient Service, Stanford Hospital & Clinics
2010Board of Directors, Association of Northern California Oncologists
Awards:
2002
2003
2003
2004
2006
2007
2008
2009
Oncology Clinical Fellows’ Teaching Award
Medicine Chief Residents Teaching Award
Oncology Clinical Fellows’ Teaching Award
Oncology Clinical Fellows’ Teaching Award
Oncology Clinical Fellows’ Teaching Award
Oncology Clinical Fellows’ Teaching Award
Oncology Clinical Fellows’ Teaching Award
Oncology Clinical Fellows’ Teaching Award
Invited Papers & Presentations
Local
1997
Hormone Use in Prostate Cancer - Stanford Medical Center
1997
Carcinoma Unknown Primary - Stanford Medical Center
2000
What’s next after hormones in prostate cancer – Spago’s, Palo Alto
2000
Advanced Testicular Cancer - Stanford Medical center
2000
Chemotherapy in prostate cancer - Emile’s, San Jose
2001
Prostate Cancer, Lane Lecture Series - Stanford, CA
2001
Small Cell Lung Cancer - Stanford Medical Grand Rounds
2
2002
2002
2002
2004
2004
2005
2005
2005
2005
2006
2007
2008
2009
2010
Regional
1999
1999
2000
2001
2001
2002
2002
2002
2003
2003
2003
2003
2004
2004
2004
2004
2004
2005
2005
2006
2006
2006
2006
2007
Controversies in Hormonal Therapy in Prostate Cancer - Stanford Medical
Center
Hormones and Prostate Cancer - Stanford Medicine Grand Rounds
Prostate Tumor Board – Spago’s, Palo Alto, CA
Node Positive Bladder Cancer - Urology Grand Rounds, Stanford, CA
Advanced Bladder Cancer - Stanford Medical Center
Clinical Trials in Urologic Oncology - Stanford, CA
Metastatic Renal Cell Cancer - Stanford Medical Center
Prostate Cancer, Round Table Discussions, Menlo Park, CA
ASCO Update in Urologic Oncology - Stanford Medical Center
Palliative Care-Oncologic Emergencies, Stanford University, CA
Metastatic Renal Cell Cancer- Urology Grand Rounds, Stanford
ASCO Update in Urologic Oncology - Stanford Medical Center
ASCO Update in Urologic Oncology - Stanford Medical Center
ASCO Update in Urologic Oncology - Stanford Medical Center
Advances in Testicular Cancer - CME Conference at Napa, CA
Advanced Metastatic Prostate Cancer - Clairemont, Oakland
GU tumor Board - UCSF/Stanford CME conference, Napa, CA
GU tumor Board - UCSF/Stanford CME conference, Napa, CA
Advanced Bladder Cancer - Annual Urology Symposium, Palo Alto, CA
GU tumor Board - UCSF/Stanford CME conference, Napa, CA
Adjuvant Therapy in Bladder Cancer-A careful standard - Annual Urology
Symposium, Palo Alto, CA
Chemotherapy for Stage I NSGCT - Annual Urology Symposium, Palo Alto, CA
Second Line Hormones in Prostate Ccancer - Annual Urology Symposium,
Palo Alto, CA
Novel Therapies in Advanced Prostate Cancer - Annual Urology
Symposium, Palo Alto, CA
GU tumor Board - UCSF/Stanford CME conference, Napa, CA
Renal Cell Carcinoma - Abgenix, Fremont, CA
Adjuvant Chemotherapy - High Risk Prostate cancer. Annual Urology
Symposium, Palo Alto, CA
GU tumor Board - UCSF/Stanford CME conference, Napa, CA
Renal Cell Carcinoma - Genentech, CA
Invasive Bladder Cancer - Hoag Cancer Center, CA
Advanced Prostate Cancer - St Josephs Hospital, Orange, CA
GU tumor Board – UCSF/Stanford CME conference, Napa, CA
Taxanes in Prostate Cancer - Annual Urology Symposium, Palo Alto, CA
Metastatic Renal Cell Cancer - Visalia, CA
Node positive Prostate Cancer - Annual Urology Symposium, Palo Alto,
GU Tumor Board - UCSF/Stanford CME conference, Napa, CA
New Drugs in Renal Cancer - Annual Urology Symposium, Palo Alto, CA
Bladder Cancer - St Joseph’s Hospital, Stockton, CA
3
2007
2007
2008
2009
2009
2010
2010
National
1995
1995
1995
1995
1999
2002
2003
2005
2006
2007
2007
2007
2008
2008
2009
2010
2010
International
2005
2006
2007
2008
2009
GU Tumor Board – UCSF/Stanford CME conference, Napa, CA
Kidney Cancer - California Kidney Cancer Foundation, San Francisco, CA
ASCO GU Update, ANCO - San Francisco, CA
ASCO GU Update, Scripps Clinic - San Francisco, CA
Chemotherapy and bladder cancer, BCAN - San Francisco, CA
ASCO GU Update, Scripps Clinic - San Francisco, CA
Prostate Cancer- New Therapy - Oncology Congress, San Francisco, CA
Antiandrogen withdrawal syndrome - American Urologic Association Meeting, San
Francisco, CA
Doxorubicin and dose escalated cyclophosphamide with Granulocyte colony
stimulating factor support for hormone refractory prostate cancer” - Annual
Meeting of the American Society of Clinical Oncology, Los Angeles, CA
Hormonal Therapy in Prostate Cancer - VA Grand Grounds, Houston, TX
Use of Tumor Markers - Grand Rounds, Baylor School of Medicine,
Houston, TX
Management choices in Stage I NSGCT - Annual meeting of American
Society of Clinical Oncology, Atlanta, GA
Metastatic Bladder & Prostate Cancer - UCD Fellow Symposium, Davis, CA
Prostate Cancer - Colorado Springs, Denver, CO
Bone Related Events in High Risk Prostate cancer - San Francisco, CA
Continuous dosing sunitinib in RCC - Kidney Cancer Symposium, Chicago, IL
Metastatic Renal Cell Cancer - Grand Rounds Methodist Hospital, Houston, TX
Targeted Therapy - Clinical Symposium, ASCO, Chicago, IL
Targeted Therapy in Kidney Cancer - National Comprehensive Cancer
Network, Palo Alto, CA
Bladder Cancer - Western Section, American Urologic Association, Monterey, CA
Kidney Cancer - Wayne State, Michigan
Kidney Cancer - Kona, HI
Kidney Cancer - La Junta, CO
Kidney Cancer, VA Medical Center - Amarillo, TX
Metastatic Renal Cell Cancer, Singapore General Hospital
International Global Forum: Manila & Hong Kong
New Drugs in Kidney Cancer, Mumbai, India
Kidney Cancer, Beijing
Hormonal Therapy in Prostate Cancer, National Comprehensive Cancer
Network, Abu Dhabi
Journal Reviewer
2004
Adhoc reviewer, Journal of Urology
2005
Adhoc reviewer, Cancer
2006
Adhoc reviewer, Journal of Urology
4
2007
2008
2009
Adhoc reviewer, Journal of Urology
Adhoc reviewer, Journal of Clinical Oncology
Adhoc reviewer, Cancer
Publications (50 total; 48 published, 1 accepted, 1 submitted):
1. Raschke RA, Reilly BM, Guidry FR, Fontana JR, Srinivas S. The weight-based
heparin dosing nomogram compared with a standard care nomogram. A randomized
controlled trial. Ann Intern Med 119: 874, 1993.
2.
Reilly BM, Raschke R, Srinivas S, Nieman T. Intravenous heparin dosing: patterns
and variations in internists practices. J General Internal Medicine 8: 536-42, 1993.
3.
Small EJ, Srinivas S. Antiandrogen withdrawal syndrome. Experience in a large
cohort of unselected patients with advanced prostate cancer. Cancer 76: 1428-34,
1995.
4.
Small EJ, Srinivas S, Egan B, McMilan A, Rearden TJ. Doxorubicin and dose
escalated cyclophosphamide with granulocyte colony stimulating factor support for
the treatment of hormone resistant prostate cancer . J Clin Oncol 14: 1617-25, 1996.
5.
Srinivas S, Freiha FS. Mahalati K. Methotrexate tolerance in ileal conduits and
neobladders. Cancer 82: 1134-6, 1998.
6.
Srinivas S, Freiha FS. Actinomycin D revisited in testicular cancer. A case report.
Tumori 85: 79-80, 1999.
7.
Rubin DL, Gennari JH, Srinivas S, Yuen A, Kaizer H, Mausen MA, Silva JS. Tool
support for authorizing eligibility criteria for cancer trials. Proc AMIA Symp 1999:
369-73.
8.
Srinivas S, Varadhachary G. Spontaneous pneumothorax in malignancy: A case
report and review of the literature. Ann Oncol 11:887-9, 2000.
9.
Srinivas S. High dose chemotherapy in germ cell tumors. Oncology 14:1419-23,
2000.
10. Durski JM, Srinivas S, Segall G. Comparision of FDG-PET and bone scans for
detecting skeletal metastases in patients with non-small cell lung cancer. Clin
Positron Imaging 3:97-105, 2000.
11. Srinivas S. Terris MK. Management choices in stage I non-seminomatous. Germ
Cell Tumor UroOncology, 2001 1; 1-4
5
12. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density
over 10 years of androgen deprivation therapy in patients with prostate cancer.
Urology 57: 127-32, 2001.
13. Srinivas S. Utility of bone scan post primary therapy in prostate cancer.
UroOncology, 2:37-39, 2002.
14. Srinivas S, Jain.M, Segall G. Residual masses post chemotherapy in germ cell
tumors: role of fluorodeoxyglucose positron emission tomography scans.
UroOncology, 2:153-55, 2002.
15. Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging
of esophageal cancer. Arch Surg 137:1001-6, 2002.
16. Morgan K, Srinivas S, Freiha F. Synchronous solitary metastases of transitional cell
carcinoma to the testis. Urology 64:808-9, 2004.
17. Murphy JC, Srinivas S, Terris MK. Flutamide administration at 500 mg daily has
similar effects on serum testosterone to 750 mg daily. J Androl 25:630-634, 2004.
18. Srinivas S, Guardino AE. A non-platinum combination in metastatic transitional
cell carcinoma. Am J Clin Oncol. 28:114-8, 2005.
19. Srinivas S, Guardino AE. A lower dose of thalidomide is better than a high dose in
metastatic renal cell carcinoma. BJU Int. 96: 536-9, 2005.
20. Srinivas S, Freiha F. Node Positive Bladder Cancer. Arab J Urology 3, 7-11, 2005.
21. Badger J, Kang S, Uzieblo A, Srinivas S. Photorecall with gemcitabine following
UVB therapy. J Clin Oncol 23: 7224-5, 2005.
22. Srinivas S, Colocci N, Feldman D. A phase II study evaluating oral triamcinalone
in patients with androgen independent prostate cancer. Urology 67:1001-6, 2006.
23. Srinivas S, Colocci N. Bone related events in high risk prostate cancer. Review. J
Urol 176:S50-4, 2006.
24. Srinivas S. Colocci N. Non-platinum combinations in advanced bladder cancer.
Expert Rev Anticancer Ther 6:887-94, 2006.
25. King CR, McNeal JE, Gill H, Brooks JD, Srinivas S, Presti JC, Jr. The reliability
of small amounts of cancer in prostate biopsies to reveal the pathologic grade.
Urology 67: 1229-36, 2006.
Contributed to the design of the study, analyze the data and the manuscript
6
26. Liu IJ, Lai YH, Espiritu JI, Segall GM, Srinivas S, Nino-Murcia M, Terris MK.
Evaluation of fluorodeoxyglucose positron emission tomography imaging in
metastatic transitional cell carcinoma with and without prior chemotherapy. Urol Int
77: 69-75, 2006.
Contributed to the original idea, helped with patient identification and analyze
the results
27. Li M, Srinivas S. Acute pancreatitis associated with sorafenib. South Med J 100:
909, 2007.
28. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S,Vaishampayan
U,Drabkin H, Dutcher J,Ryba S,Xia O,Scappaticci FA, and McDermott D.
Randomized phase II study of erlotinib combined with bevacizumab compared with
bevacizumab alone in metastatic renal cancer. J Clin Oncol 25:4536-41, 2007.
Limited multiinstituitional trial; authorship based on number of patients
enrolled.
29. Feldman D, Krishnan A, Moreno J, Swami S, Peehl D, Srinivas S. Vitamin D
inhibition of the prostaglandin pathway as therapy for prostate cancer. Review. Nutr
Rev: 65: S113-5, 2007.
30. Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ,
Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar
G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S,
Twardowski P, Urban DA, Walsh PC; National Comprehensive Cancer Network.
Prostate cancer. Clinical practice guidelines in oncology.J Natl Compr Canc Netw:
7: 650-83, 2007.
31. Harshman LC, Srinivas S. Current status of cytoreductive nephrectomy in
metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 7:1749-61, 2007.
32. Harshman LC, Mingqing Li, Srinivas S. The combination of thalidomide and
capecitabine in metastatic renal cell carcinoma---is not the answer. Am J Clin
Oncol 31:417-423, 2008.
33. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardioxicity associated with the
cancer therapeutic agent sunitinib malate. Ann Oncol. 19: 1613-8, 2008.
34. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R,
Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients
with metastatic renal cell carcinoma. Cancer 113: 72-7, 2008.
7
35. Srinivas S, Feldman D. A phase II trial of calcitriol and naproxen in recurrent
prostate cancer. Anticancer Res. 2009 Sep;29(9):3605-10
36. Agarwal R, Dvorak CC, Stockerl-Goldstein KE, Johnston L, Srinivas S. High dose
chemotherapy followed by stem cell rescue for high risk germ cell tumors: the
Stanford experience. Bone Marrow Transplant. 2009 Apr;43(7):547-52
37. Escudier B, Johannsen M, Gillessen S, Harmenberg U, Srinivas S, Mulder S,
Fountzilas G, Peschel C, Flodgren P, Maneval E, Chen E, Vogelzang N. A phase II
study of sunitinib administered in a continuous once-daily dosing regimen in
patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009
Sep 1;27(25):4068-75. Epub 2009 Aug 3.
Limited multi instituitional trial; involved in trial design and recruitment of
patients and analyzing the data.
38. Krishnan AV, Srinivas S, Feldman D. Combination therapy with calcitriol and
non-steroidal anti-inflammatory drugs in the treatment of prostate cancer. Dermato
Endocrinolgy 2009; 1: 7-11
I was the PI on a clinical trial using this combination. Shared the trial
information and the data as part of this paper
39. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC,
Ringuette S, Wit ED, Pautret V, and George C. Vinflunine in Platinum-Pretreated
Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Results of a
Large Phase 2 Study. Cancer. 2009 Jun 17
Limited multi instituitional trial; involved in trial design and recruitment of
patients and analyzing the data
40. Harshman LC ,Kuo CJ,Wong BY, Vogelzang NJ, Srinivas S. Increased
Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma.
Cancer Invest. 2009 Jul 13:1
41. Srinivas S, & Harshman LC.A Phase II study of docetaxel and oxaliplatin for
second line treatment of transitional cell carcinoma of the urothelium.
Chemotherapy. 2009 Jul 27;55(5):321-326
42. Harshman LS, Srinivas S, and Chung . Laparoscopic Radical Nephrectomy after
Caval Tumor Thrombus Shrinkage with Sunitinib. Nat Rev Urol. 2009
Jun;6(6):338-43.
Helped with design, identifying patients
8
43. Gralow JR, Biermann, SJ, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro
CL, Shields A, Smith MR, Srinivas S and Van Poznack CH. NCCN Task Force
Report: Bone Health in cancer care; JNCCN 2009
44. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI , Srinivas S. RRM1
expression in muscle invasive locally advanced urothelial cancer may correlate with
age. BJU Int. 2010 Apr 28.
45. Pili R, Rosenthal MA, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong
S and Clingan P. Randomized Phase II Study of the Addition of ASA404
(Vadimezan, 5,6 Dimethylxanthenone-4-acetic acid/DMXAA) to Docetaxel in
Castration-Refractory Metastatic Prostate Cancer. Clin Cancer Res. 2010 May
15;16(10):2906-14.
Limited multi instituitional trial; involved in trial design and recruitment of
patients and analyzing the data
46. Yu JR, Harshman LC, Gill HS, Srinivas S, and Chung BI. Surgical Complications
Associated with Presurgical Tyrosine Kinase Inhibition Prior to Cytoreductive
Surgery for Advanced Renal Cell Carcinoma. Submitted European Urology
Helped with design, identifying patients
47.
Dreicer R, Garcia J, Rini B, Vogelzang N, Srinivas S, Somer B, Zhao YD,
Kania M, Raghavan D. Oral enzastaurin in prostate cancer: A two cohort phase II
trial in patients with PSA progression in the non-metastatic castrate state and
following docetaxel-based chemotherapy in the castrate metastatic setting.
Investigational New Drugs, Apr 6 2010.
Participated in the trial design, recruitment of patients
48. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA,
George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH,
Macvicar G, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Roth BJ, Shrieve
DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice
guidelines in oncology: prostate cancer.J Natl Compr Canc Netw. 2010
Feb;8(2):162-200
49. Sonn GA, Shinghal R, Yu JR, Chung BI, Srinivas S, Presti JC Jr., and Leppert JT.
Kidney Cancer Outcomes in the VA health Care System: Analaysis of 12,112
Patients from the VA Central Cancer Registry. (submitted)
Contributed to the idea, analysis of the data
50. Nadauld LD, Miller MB & Srinivas S. Pyoderma Gangrenosum with the Use of
Sunitinib. J Clin Oncol (accepted)
9
Non Peer Reviewed (2 total, 1 published, 1 accepted)
1. Harshman LC, Srinivas S. Continuous therapy of sunitinib in patients with
metastatic renal cell cancer. Editorial. Onkologie 31:432-433, 2008.
2. Harshman LC , and Srinivas S. The bevacizumab experience in advanced renal cell
carcinoma. Oncology Targets and Treatment (accepted)
Book Chapters (5)
1. Srinivas S. Second line hormonal therapy in Prostate Cancer (2003). American
Cancer Society Atlas of Clinical Oncology, Prostate Cancer.
2. Srinivas S. Urologic Complications of Cancer Treatment- (2004) Springer -Verlag
Oncology: An Evidence Based Approach
3. Yamada Y, Harshman LC, Schefter T, Rabinovitch RA, Chung BI, Srinivas S.
(2008) Cancer of the kidney. In: The Textbook of Radiation Oncology, 3rd Edition.
S. Leibel and T.L. Phillips, eds. Philadelphia, Elsevier
4. Harshman LC, Srinivas S, Symanowski J, Vogelzang NJ. (2008) Formulating the
questions and objectives. In: Fundamentals of Oncology Clinical Trials: The Art
and Science Behind Successful Clinical Trials. K. Kelly and S. Halabi, eds. New
York, Demos Medical Publishing.
5. Presti J, Srinivas S & King C. (2008)Cancer of the Testes. In: The Textbook of
Radiation Oncology, 3rd Edition. S. Leibel and T.L. Phillips, eds. Philadelphia,
Elsevier
10
Abstracts (38):
1. Small EJ, Ernest ML, Srinivas S. The use of Carboplatin instead of cisplatin in the
treatment of advanced Transitional cell Carcinoma(TCC), Amer. Urol. Assoc. Ann.
Meeting, 1994.
2.
Small EJ, Reardon T, Srinivas S .Doxorubicin and dose escalated
cyclophosphamide with Granulocyte colony stimulating factor support for hormone
refractory prostate cancer, Proc Amer Soc Clin Onol, 1994.
3.
Small EJ, Srinivas S. Effect of prior radiotherapy on response and survival in
hormone refractory prostate cancer patients, Proc Amer Soc Clin Onol, 1994.
4.
Srinivas S, Freiha F, Segall G.PET in evaluation of residual masses in testicular
cancer; Proc Amer Soc Clin Onol #1327;1998
5.
Srinivas S, Terris M. Management choices in Stage I NSGCT: Proc Amer Soc Clin
Onol, 1999
6.
Vempaty H, Srinivas S. Cisplatin in Elderly; Proc Amer Soc Clin Onol 1999
7.
Terris MK, Srinivas S. Comparative study of the clinical efficacy of three dosing
regimens of Flutamide. AWUA, 1999
8.
Kiratli JB, Srinivas S, Terris MK. Effect of androgen deprivation on bone density
in prostate cancer patients. AWUA,1999
9.
Srinivas S. Bone scan utility in Prostate cancer post primary Therapy. Proc Amer
Soc Clin Onol , 2000
10. Srinivas S. Thalidomide in metastatic renal cell carcinoma. Proc Amer Soc Clin
Onol , 2001
11. Guardino AE, Srinivas S. Phase II trial of Gemcitabine and Paclitaxel
Chemotherapy for Advanced Urothelial Malignancies. Proc Amer Soc Clin Onol
2002
12. Hart L, Redfern C, Srinivas S, Saltzman M, Baron A, Atiba J, Strupp J, Christie R,
Schliebner S, Ryan K, Sandler A, Sing A, Ahmann F. A phase II study of SGN-015
combined with docetaxel in patients with hormone refractory prostate carcinoma.
Proc Amer Soc Clin Onol 2002
13. Srinivas S and Guardino AE. Randomized phase II trial of high and low dose
thalidomide in metastatic renal cell carcinoma. Proc Amer Soc Clin Onol, 2002
11
14. Srinivas S., Beck J.T., Vesole D., McEwen C., Bhatnagar A., and Valone F. Initial
Results of a Phase I/II Study of Gallium Maltolate in Patients with Various
Refractory Malignancies. EORTC 2002, Germany.
15. Redfern CH, Hart L, Srinivas, S, Hall S, McCune D, Boyd T, Sandler AS, Sing AP,
Siegall C, Ahmann FR. A phase II study of SGN-15 (cBR96-doxorubicin
immunoconjugate) combined with docetaxel in patients with hormone refractory
prostate carcinoma (HRPC). Proc Amer Soc Clin Onol, 2003
16. Lum BL, Srinivas S, Beck JT, Vesole D, Largey M, Valone FH, Sayre PH. Phase I
trial of oral gallium maltolate in refractory malignancies. Proc Amer Soc Clin Onol,
2003
17. Freiha FA, Srinivas S. Invasive Renal Pelvis Transitional Cell Carcinoma. Proc
Amer Soc Clin Onol, 2004
18. Guardino AE, Srinivas S. Gemcitabine and Paclitaxel Chemotherapy Effective for
Good Risk Advanced Urothelial Malignancies. Proc Amer Soc Clin Onol, 2004
19. Srinivas S, Balu V, King C. Utility of Serum prostate specific antigen Doubling
time (PSADT) in patients with Androgen Independent Prostate Cancer. Proc Amer
Soc Clin Onol, 2005
20. Srinivas S, Colocci N, Feldman D. A phase II study evaluating oral Triamcinalone
in patients with androgen independent prostate cancer. Proc Amer Soc Clin Onol,
2005
21. Pachynski RK, King CR, Srinivas S. Prostate Specific Antigen Doubling Time
(PSADT) in Patients with Hormone Refractory Prostate Cancer (HRPC) undergoing
Docetaxel Chemotherapy as a Predictor of Overall Survival. Proc Amer Soc Clin
Oncol 2007
22. Srinivas S, Roigas J, Gillessen S, Harmenberg U, De Mulder PH, Fountzilas G,
Vogelzang N, Peschel C, Flodgren B, Escudier B. Continuous daily administration
of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma
(mRCC) – updated results. Proc Amer Soc Clin Oncol 2007
23. Katznelson L, Kent K, Srinivas S. The effects of intermittent androgen deprivation
therapy (ADT) and zoledronic acid administration on bone density in patients with
prostate cancer. Proc Amer Soc Clin Oncol 2007
24. Stadler WM, Figlin RA, Ernstof MS, Curti B, Pendergrass K, Srinivas S, Canfield
V, Weissman C, Poulin-Costello M, Bukowski R, and on behalf of the ARCCS
Investigators. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded
12
access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell
carcinoma (RCC). Proc Amer Soc Clin Oncol 2007
25. Colocci N, King C, Brooks J, Gill H, Presti J, Srinivas S. Adjuvant doxetaxel
chemotherapy with abbreviated hormonal therapy in patients with high-risk prostate
cancer. Proc Amer Soc Clin Oncol 2007
26. Ross R, Stein M, Sarantopolous J, Eisenberg P, Logan T, Srinivas S, Rosenberg J,
Vaishampayan U. A phase 2 study of the c-Met RTK inhibitor XL880 in patients
(pts) with papillary renal-cell carcinoma (PRC). Proc Amer Soc Clin Oncol 2007
27. Vaughn D, Srinivas S, Stadler W, Pili R, Petrylak D, Sternberg C, Smith D, Nason
S, De Wit E, George C. Phase II study of single-agent vinflunine in platinumrefractory advanced/metastatic transitional cell carcinoma (TCC) of the urothelium.;
Proc Amer Soc Oncol 2007
28. Srinivas S, Harshman LC, Feldman DR. A phase II trial of calcitrol and naproxen
in recurrent prostate cancer. Proc Amer Soc Oncol 2008
29. Harshman LC, Kuo CJ, Wong , Vogelzang NJ, Srinivas S. Bevacizumab-associated
erythrocytosis in advanced renal cell carcinoma (RCC) Proc Amer Soc Oncol 2008
30. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the
cancer therapeutic agent sunitinib malate. Proc Amer Soc Oncol 2008
31. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Tibshirani R, Srinivas S.
Correlation of RRM1 expression in muscle invasive locally advanced urothelial
cancer with age. J Clin Oncol 27, 2009 (suppl; abstr e16021
32. Witteles RM, Harshman LC, Telli M, Srinivas S. Prospective cardiotoxicity
screening during tyrosine kinase inhibitor therapy for renal cell carcinoma: An
institutional experience. J Clin Oncol 27, 2009 (suppl; abstr e16003
33. Harshman LC, Telli ML, Witteles RM, Srinivas S. Low incidence of symptomatic
cardiotoxicity associated with sorafenib in patients with metastatic renal cell
carcinoma (mRCC): An institutional experience
34. Harshman LC, McMillan A, Srinivas S. Treatment of refractory metastatic renal
cell carcinoma (RCC) with bevacizumab and RAD001. Clin Oncol 28:15s, 2010
(suppl; abstr TPS236
35. Harshman LC, Yu R, Gill HS, Srinivas S, Chung BI. Surgical complications
associated with presurgical tyrosine kinase inhibition for advanced renal cell
carcinoma (RCC) 2010 Genitourinary Cancers Symposium Abstract No: 404
13
36. Patel P, R. Balise R, Srinivas S. Predictive value for relapse of variation in alphafetoprotein (AFP) levels in patients who are in remission from germ cell cancer. J
Clin Oncol 28, 2010 (suppl; abstr e15119
37. Alva AS, Agarwal N, Siefker-Radtke AO, Roth BJ, Smith DC, Daignault S,
Srinivas S, Bradley DA, Hussain M. Targeting epidermal growth factor receptor
(EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with
gemcitabine (G) with or without cetuximab. J Clin Oncol 28:15s, 2010 (suppl; abstr
TPS239)
38. Srinivas S, Harshman LC, Feldman D. Effect of fulvestrant on PSA doubling time
in patients with castration-resistant prostate cancer (CRPC).J Clin Oncol 28, 2010
(suppl; abstr e15112)
Ongoing Research Support
STUDY: A phase II study of pazopanib in combination with weekly
paclitaxel in refractory urothelial cancer.
04/06/10 - 04/30/12
ROLE: PI
TYPE OF STUDY: Investigator Initiated
SPONSOR: GlaxoSmithKline
PLANNED NUMBER OF SUBJECTS: Stanford 33
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Temsirolimus, an mTor inhibitor to reverse androgen insensitivity in patients
with castrate resistant prostate cancer.
05/27/09 - 05/27/12
ROLE: PI
TYPE OF STUDY: Investigator Initiated
SPONSOR: National Comprehensive Cancer Network
PLANNED NUMBER OF SUBJECTS: Stanford 30
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Treatment of Refractory Metastatic Renal Cell Carcinoma with Bevacizumab
and RAD0001
dates?
ROLE:co- PI
TYPE OF STUDY: Investigator Initiated
SPONSOR: Novartis Pharmaceuticals Corp
PLANNED NUMBER OF SUBJECTS: Stanford 30
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: A Phase II Study of Sorafenib in Patients with Metastatic Renal Cell Carcinoma.
ROLE: PI
07/16/07 - 07/15/11
TYPE OF STUDY: Investigator Initiated multi instituitioal trial
SPONSOR: Bayer Corporation
PLANNED NUMBER OF SUBJECTS: Stanford 10 Other 10
14
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Phase II Study of Granulocyte-macrophage Colony Stimulating Factor Plus
Mitoxantrone for the treatment of Hormone Refractory Prostate Cancer.
ROLE: PI?
04/25/06 - 03/31/11
TYPE OF STUDY: Investigator Initiated
SPONSOR: Bayer Corporation
PLANNED NUMBER OF SUBJECTS: Stanford 10
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Fulvestrant in Hormone Refractory Prostate Cancer
ROLE: PI
TYPE OF STUDY: Investigator Initiated
SPONSOR: Astra Zeneca
PLANNED NUMBER OF SUBJECTS: Stanford 10
REGISTRATION NUMBER AT ClinicalTrials.gov:
09/01/06 - 08/31/10
STUDY: A Phase 1b/2 Study to Assess the Safety and Efficacy in AMG102 in
Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated
Castrate Resistant Prostate Cancer
11/18/08 - 11/30/12
ROLE: PI
TYPE OF STUDY: Industry-initiated multi-institutional trial
SPONSOR: Amgen
PLANNED NUMBER OF SUBJECTS: Stanford 3 Other __
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Phase II Randomized Trial of Gemcitabine and Cisplatin with or without
Cetuximab in Patients with Urothelial Carcinoma.
04/01/09 - 12/31/10
ROLE: PI
TYPE OF STUDY: Industry-initiated multi-institutional trial
SPONSOR: National Comprehensive Cancer Network
PLANNED NUMBER OF SUBJECTS: Stanford 5 Other 60
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: Comparison of DCE MRI and FDG PET/CT for Monitoring Targeted Therapy
in Renal Cell Cancer (Quan, PI)
10/01/09 - 09/30/11
ROLE: Co-PI
TYPE OF STUDY: Investigator Initiated single institution trial
SPONSOR: National Institutes of Health
PLANNED NUMBER OF SUBJECTS: Stanford 20
REGISTRATION NUMBER AT ClinicalTrials.gov:
15
STUDY: A Phase Ib, Open-label, Dose-finding Study to Evaluate the Safety of AV-951 in
Combination with Temsirolimus in Subjects with Metastatic Renal Cell Carcinoma.
ROLE: PI
08/26/08 - 07/31/11
TYPE OF STUDY: Industry-initiated multi-institutional trial
SPONSOR: Aveo Pharmaceuticals, Inc.
PLANNED NUMBER OF SUBJECTS: Stanford 6 Other __
REGISTRATION NUMBER AT ClinicalTrials.gov:
STUDY: A Phase 2 Study of the c Met RTK Inhibitor XL880 in Subjects with Papillary
Renal-cell Carcinoma (PRC).
10/01/06 - 12/31/10
ROLE: PI
TYPE OF STUDY: Industry-initiated multi-institutional trial
SPONSOR: GlaxoSmithKline
PLANNED NUMBER OF SUBJECTS: Stanford 5 Other __
REGISTRATION NUMBER AT ClinicalTrials.gov:
Completed Research Support
Celgene, Inc., Srinivas (PI)
Thalidomide in metastatic renal cell carcinoma investigator initiated
12/98-12/02
Eli Lilly, Srinivas (PI)
Taxol/Gemcitabine in Bladder Cancer
5/98-5/02
Sanofi-Synthelabo, Srinivas (PI)
02/04/04-01/15/07
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer.
Celgene Corporation, Srinivas (PI)
01/20/03 to 01/31/05
A Phase II Trial Of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma.
Novacea, Inc.
02/06/06 - 10/31/08
A Phase II Trial of Calcitrol and Naprosyn in Recurrent Prostate Cancer
16
Novartis Pharma AG CZOL446EUS4
09/15/03 - 06/30/09
Zoledronic Acid with Intermittent Hormonal Therapy in Patients with Prostate Cancer
Genentech, Inc. AVF4304S
07/07/08 - 07/06/11
Treatment of refractory metastatic renal cell carcinoma with Bevacizumab and RAD001
Infinity Pharmaceuticals, Inc. IPI-504
04/03/08 - 04/02/10
A Phase 2, Open-label Study to Investigate the Pharmacodynamics and Clinical Activity of
IPI-504 in Patients with Castration-resisitant Prostate Cancer
Agennix, Inc., Srinivas (PI)
08/04/04 –07/31/06
A Multi-Center, Phase 2, Open Label Study of Safety and Efficacy of Oral Recombinant
Human Lactoferrin (rhLF) Monotherapy in Patients with Advanced Renal Cell Carcinoma
(RCC), Who Have Failed at Least One Regimen of Systemic Therapy for Renal Cell
Carcinoma. This contract will fund the cost of the clinical trial. Overlap: None
Abgenix, Inc., Srinivas (PI)
10/01/03-09/30/06
A Two Part, Multiple Dose Clinical Trial Evaluating the Safety and Effectiveness of Two
Dose Levels of ABX-EGF in Patients with Renal Carcinoma. This contract will fund the
cost of the clinical trial. Overlap: None
Genentech, Inc., Srinivas (PI)
04/01/04 –03/31/06
A Phase II, Multicenter, randomized, double-blind clinical trial to evaluate the efficacy and
Safety of Tarceva (Erlotinib hydrochloride) in combination with Avastin
(Bevacizumab) versus Avastin alone for treatment of Metastatic renal Cell Carcinoma.
This contract will fund the cost of the clinical trial. Overlap: None
Astra Zeneca
10/08/08 - 09/30/10
A Phase II, Single Arm, Single Agen, Multi-centre, Adaptive 2-Stage Study to Evaluate the
Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with
Recurrent Urothelial Cancer.
Eli Lilly And Company
01/26/07 - 01/25/10
Phase 2 Trial of Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1)
During Hormonal Manipulation, and (2) After First-line Cytotoxic Chemotherapy
Pfizer Pharmaceuticals
06/23/05 - 06/30/09
A Phase 2 Efficacy and Safety Study of SU011248 Administered in a Continous Daily
Regimen in Patients with Cytokine Refractory Metastatic Renal Cell Carcinoma
Antisoma
08/05/05 - 08/04/09
An Open Label, Randomized, Phase II Study of AS1404 in Combination with Docetaxel in
Patients with Hormone Refractory Metastatic Prostate Cancer
Eli Lilly:
17
Phase 2 Trial of Oral Enzastaurin in Prostate Cancer Patients who have rising PSA (1)
during Hormonal Manipulation, and (2) After First-line Cytotoxic Chemotherapy.
18
Mentoring Fellows and Junior Faculty:
Date
2008-present
2007-2010
2006-2009
2004-2007
2003-2006
2003-2006
2003-2006
Name
Priti Patel
Mehrdad Mobasher
Russell Pachynski
Shane Dormady
Natalia Colocci
Brian Lu
Tiffany Svahn
Current Position
Fellow - Oncology
Genentech
Postdoctoral fellow/Instructor
Private Practice, CA
Palto Medical Foundation
Schering Plough, NJ
John Muir Medical Center
19